A5004823704- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Biosimilars and Bioanalytical Methods
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Artificial Intelligence in Healthcare and Education
- Heart rate and cardiovascular health
- Heart Rate Variability and Autonomic Control
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Healthcare Systems and Public Health
- Radiopharmaceutical Chemistry and Applications
- Non-Invasive Vital Sign Monitoring
Professional Solutions (United States)
2024
Perm Regional Oncology Center
2013-2014
.
e13500 Background: BCD-021 is a bevacizumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence to innovator drug Avastin. Methods: 28 patients with advanced non-squamous NSCLC (stage IIIb/IV) were enrolled in the study. Patients randomly assigned into 2 groups at ratio 1:1 receive or Avastin dose 15 mg/kg combination paclitaxel (175 mg/m2) carboplatin (AUC 6 mg/ml×min) every 3 weeks. The primary endpoint was...
e11576 Background: BCD-022 is a trastuzumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence to innovator drug trastuzumab. Methods: 46 patients with HER2(+) mBC were enrolled in the study. Patients randomly assigned into 2 groups at ratio 1:1 receive or (a single loading dose 8 mg/kg maintenance 6 mg/kg) paclitaxel (175 mg/m2) every 3 weeks. The primary endpoint was AUC(0-504), secondary endpoints included...
BACKGROUND: Increased resting heart rate (HR) is an independent risk factor for overall mortality, sudden cardiac death, and death from cardiovascular diseases (CVD) a worsening CVD patients’ prognosis. Moreover, HR easy to measure monitor independently using various devices. The accuracy of personal wearable devices used in assessing should be investigated. AIM: To evaluate the determination with device (PWD). MATERIALS AND METHODS: An open, observational, single-center study was performed....
e20593 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa polyethylene glycol (PEG) is approved for treatment chemotherapy-associated neutropenia. BCD-017 (empegfilgrastim) a covalent conjugate with 30 PEG. Increased molecular weight PEG molecule may provide additional benefits compared to pegfilgrastim. Methods: To compare efficacy safety at 3 mg 6 doses an open-label, randomized, active-comparator, non-inferiority trial was conducted. 60 patients histologically or cytologically...
РЕЗУЛЬТАТЫ МНОГОЦЕНТРОВОГО ДВОЙНОГО СЛЕПОГО РАНДОМИЗИРОВАННОГО КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ ПЕРВОЙ ФАЗЫ ПРЕПАРАТА BCD-022 ПО СРАВНЕНИЮ С ПРЕПАРАТОМ ГЕРЦЕПТИН®, ПРИМЕНЯЕМЫХ В СОЧЕТАНИИ ПАКЛИТАКСЕЛОМ У БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ